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WOODRUFF and Symes (1962a) reported that the growth of subcutaneous
mouse mammary carcinoma transplants, in isogenic hosts, could be retarded by
the administration of sub-lethal whole body irradiation followed by intravenous
injection of allogeneic immunologically competent cells. Destruction of the
tumour, however, could only be achieved at the expense ofkilling the host through
the effects of concomitant graft-versus-host disease.
It therefore seemed desirable to seek methods whereby the graft-versus-host
reaction could be reduced whilst retaining or increasing the graft-versus-tumour
effect. With this in mind, Woodruff, Symes and Boak (unpublished) repeated
the experiments cited above with the difference that allogeneic cells were injected
intraperitoneally in the treatment of intraperitoneal tumour transplants. The
result of this immediate intimate contact between the donor spleen and tumour
cells was a significant prolongation ofhost survival with minimal graft-versus-host
disease; however, no animals were " cured ".
An alternative approach designed to elucidate the cell type responsible for
the anti-tumour effect was that ofWoodruff, Symes and Stuart (1963) and Wood-
ruff, Symes and Anderson (1963), who treated mice bearing transplants of the
genetically nonspecific Landschutz ascites tumour by intraperitoneal injection
of either spleen cells or thoracic duct lymphocytes from rats of an inbred strain,
previously immunized against the tumour. The therapeutic superiority of the
duct lymphocytes was clearly demonstrated.
The evidence that an immunological reaction was involved in the anti-tumour
effect may be summarized thus:
(i) The effect of immunologically competent cells from donors previously
immunized against the tumour was greater than that of non-immunized
cells (Woodruffand Symes, 1962a ; Woodruff, Symes and Anderson, 1963).
(ii) In experiments where tumour transplants of a parent line strain, growing
in F1 hybrid hosts, were treated by injection of immunized spleen cells
from donors of the opposite parent line, thus eliminating the necessity
for giving whole body irradiation, a significant anti-tumour effect was
obtained (Wroodruff and Boak, 1966).
It thus seemed reasonable to postulate that for a given dose of cells, pre-
immunized against the tumour, the larger the tumour the greater the anti-tumour
effect relative to the graft-versus-host reaction. Furthermore, Woodruff (1964),
following the work of Biozzi et al. (1964), suggested that the concomitant graft-
versus-host disease might be diminished by splenectomy of the treated host.EXPERIMENTS WITH IMMUNOLOGICALLY COMPETENT CELLS
The present communication describes experiments bearing on the relation of
tumour size at treatment, and host splenectomy, to the anti-tumour effect of
injected immunologically competent cells.
MATERIALS AND METHODS
General plan of the experiments
Experiment 1.-On day 0 an A-strain mammary carcinoma of recent origin
was transplanted subcutaneously into a group of isogenic hosts. Ten days later
the tumour was removed from one of these hosts and further transplanted
(i) subcutaneously into a further group of isogenic A-strain hosts, (ii) as a cell
suspension intraperitoneally into a group of CBA-strain hosts. Thus on day 14
there were two groups of A-strain host, in one of which the tumour had grown
for 14 days, and in the other for 4 days. Each mouse in both groups received
at this time a subcutaneous injection of 15 mg./kg. body weight of Melphalan,
and 24 hours later, on day 15, an intravenous injection of 20 million allogeneic
spleen cells from a suspension made by pooling the spleens from the CBA mice im-
munized on day 10. The design of this experiment is illustrated in Fig. 1.
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FiG. 1.-General plan of experiment 1.
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Experiment 2.-This was similar to experiment 1 with the addition that on
day 14, the tumour-bearing A-strain hosts were each subjected to splenectomy





ALLOGENEIC SPLEEN CELLS I.U.
FIG. 2. General plan of experiment 2.
Experiment 3.-On day 0 a group of A-strain hosts each received a subcu-
taneous transplant from the same A-strain tumour. The mice were then divided
into 3 sub-groups, in the first of which each mouse was treated on day 14 by
splenectomy and subcutaneous injection of 5 mg./kg. body weight of Melphalan,
followed 24 hours later by the intravenous injection of 60 million CBA-strain
spleen cells from donors previously immunized against the tumour. Mice in the
second sub-group were also treated by splenectomy and a similar injection of
Melphalan and spleen cells on days 28 and 29, whilst mice in the third group
were untreated.
Transplantation of tumours.-The method of Woodruff and Symes (1962b)
was used.
Observations on animals bearing tumour transplants.-The day of death was
noted for each tumour-bearing animal.
180EXPERIMENTS WITH IMMUNOLOGICALLY COMPETENT CELLS
Administration of Melphalan (L-phenylalanine mUstard).-This was by the
method of Symes (1965).
Immunizationof spleencell donors and preparation of spleen cell suspensions.-
This was as described in Woodruff and Symes (1962a).
RESULTS
Experiments 1 and 2
In both these experiments tumour size at the commencement of treatment
was significantly greater when the latter was begun on day 14 rather than on day 4
(Table I). Using Bailey's (1959) modification of Student's t test it was found
TABLE I.-Experiments 1 and 2. Tumour Size and Relative Spleen Weight at
Treatment ofA-strain MiceBearing A-strain Mammary CarcinomaTransplants,
Treated by Splenectomy and/or Melphalan and Immunized CBA-strain Spleen
Cells, 4 or 14 Days after Tumour Transplantation
Tumour 8ize (mM.)
Days of
treatment No splenectomy Splenectomy
Day 4 + 5 . 2-561-00 (9) . 2*45±0*52 (11)
Day 14 + 15 . 10-30±4-03 (10) . 10-09±3-74 (12)
Relative 8pleefl weight
Days of Wt. ofspleen mg.
treatment Wt. of mouse g. Splenectomy
Day 4 + 5 . .. . 7-092-83 (11)
Day 14 + 15 . .. . 813+183 (12)
Brackets - Number of observations.
that in the case of experiment 1, t = 7-6,f = 10-6, p < 0.001 and for experiment
2, t = 6'7, f = 11-4, p < 0 001. However, whereas in the case of experiment 1
animals treated on day 4 lived significantly longer than those treated on day 14,
the reverse was true in the case of experiment 2 where a splenectomy was per-
formed immediately before the commencement of treatment (Table II). The
dosage ofMelphalan* and spleen cells given was such that the majority ofanimals
in both experiments died from secondary disease, and if statistical comparison
TABLE II.-Experiments 1 and 2. Survival Time in Days Following Treatment of
A-strain Mice Bearing A-strain Mammary Carcinoma Transplants, Treated by
Splenectomy and/or Melphalan and Immunized CBA-strain Spleen Cells,
4 or 14 Days after Tumour Transplantation.
Days of
treatment No splenectomy Splenectomy
Day 4 + 5 .14; 10; 9; 15; 10 .4; 5; 5; 4; 5
49; 50; 8;5 74;5; 5; 7; 5; 5
Dayl4+ 15 . ; 8; 8; 8; 7 .6; 6; 8; 53; 10
6; 5; 6; 7; 8 5; 4; 11; 60; 10
52; 50
* In a subsidiary experiment, it was found that Melphalan alone, in a dose of 15 mg./kg. body
weight given immediately following splenectomy on day 14 after tumour transplantation, resulted
in a mortality of 3 animals in 8. The longevity of the 5 animals which survived treatment was not
increased by comparison with untreated controls.
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is made between the times ofdeath ofthese animals, following treatment on day 4
or 14, it is found that for experiment 1, t = 2-63, f = 69, p < 0 05 > 0 01, and
for experiment 2, t 2-64, n- 16, p < 0-02 > 0-01. Furthermore, in experi-
ment 1, 2 out of 9 animals treated on day 4 died from their tumour, and in the
case of experiment 2 the corresponding proportion for animals treated on day 14
was 4 out of 12.
No significant difference was found in the relative spleen weight when splenec-
tomy was performed on day 4 as compared with day 14 (Table I) t = 1-05,
n - 21, p < 0*4 > 0*3.
Experiment 3
In further subsidiary experiments it had been found that in splenectomised
animals, treated on day 14, reduction inthe dose ofMelphalan from 15 to 5 mg./kg.
body weight and increase in the number of immunized spleen cells injected, per
mouse, from 20 to 60 million, resulted in a marked reduction in the incidence of
death from secondary disease with no loss of therapeutic effect on the tumour.
Using animals in which splenectomy had been performed immediately before
the commencement of treatment, a comparison was therefore made between the
therapeutic effectiveness of 5 mg./kg. body weight of Melphalan and 60 million
immunizedspleen cellsinthetreatment oftumourstransplanted 28days previously
as compared with 14 days (Table III).
TABLE III.-Experiment 3. The Effect of Treating Subcutaneous A-strain Mam-
mary Carcinoma Transplants at Varying Intervals after Transplantation by
Splenectomy, Subcutaneous Injection of 5 mg./lkg. Body Weight of Melphalan,
and Intravenous Injection of 60 Million Immunized CBA-strain Spleen Cells.
Interval between
tumour trans- Size oftumour
plantation and at treatment
treatment (mm.) Mean Day of death Mean
28 days . 260; 250; 200 . 23-0 . 76; 74 78 . 70 7
240; 25-0; 1850 60; 76; 60
14days . . 120; 80; 100 . 12K1 . 49; 49; 57 . 518
150; 100; 18-0 36 60; 60
No treatment . . . 26; 47 34 . 37 2
36; 43
Tumour size at treatment on day 28 is significantly greater than on day 14, t = 5-0, n = 10,
p < 0-001.
In the case of animals treated at 14 or 28 days by splenectomy and injection of Melphalan only,
mean survival times in days from tumour transplantation, together with the number of animals in
each group (in brackets) were as follows: No treatment 39 (5), day 14, 46 (4), day 28, 39 (6).
It was found that animals treated on day 28 lived significantly longer than
those treated on day 14, t = 3 70, n = 10, p < 0 01 > 0-001, or untreated
animals t = 6-66, n = 9, p < 0-001. Animals treated on day 14 also lived
longer than untreated controls, t = 2.75, n = 9, p < 0 05 > 0-02.
DISCUSSION
In the case ofexperiment 1 it is suggested that the greater degree ofmalignant
cachexia associated with the larger tumour mass present on day 14, when com-
bined with the effects ofsecondary disease, determined the earlier death ofanimals
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treated on day 14 as compared with those treated on day 4. The absence of a
significant difference in the relative spleen weights of animals bearing a tumour
transplant for 4 or 14 days would seem to exclude the possibility that the spleen
may afford a better site for the lodgement of the donor cells in animals treated
on day 14.
However, splenectomy immediately before the commencement of treatment
(experiment 2) reversed the situation in that animals treated on day 14 now lived
longer than those treated on day 4. One ofthe major sites ofmigration for donor
immunologically competent cells following intravenous injection is the spleen
and thus its removal may deflect these cells to the tumour. In this case the larger
the tumour the greater its ability to protect the host from secondary disease.
In experiment 3 an attempt was made to exploit this apparent " focusing ",
by splenectomy, of the action of the injected cells on the tumour. It was found
that the larger the tumour treated the greater the anti-tumour effect as judged
by prolongation of host survival.
The above results suggest a peculiar advantage possessed by this form of
therapy for malignant disease, in that the more advanced the lesion, the more
effective the treatment. The further clinical application ofthis approach (Wood-
ruff and Nolan, 1963) may therefore merit consideration.
SUMMARY
The effect of treating subcutaneous A-strain mammary carcinoma transplants
in isogenic hosts, by the subcutaneous injection of Melphalan followed by the
intravenous injection of allogeneic immunologically competent cells from donors
previously immunized against the tumour, has been investigated.
It has been found that splenectomy immediately before the commencement
of treatment focuses the action of the donor cells on the tumour, and that under
these conditions the larger the tumour treated the greater the therapeutic effect
as judged by host survival.
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